deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04262141

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Investigator-Initiated Trial of the LSD1 Inhibitor IMG-7289 for the Treatment of Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) That Have Failed at Least One Standard Therapy

Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Conditions Essential Thrombocythemia Polycythemia Vera
Interventions IMG-7289
Updated 16 times since 2020 Last updated: Jan 6, 2026 Started: Oct 2, 2020 Primary completion: Oct 31, 2026 Completion: Oct 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04262141, this PHASE2 trial focuses on Essential Thrombocythemia and Polycythemia Vera and remains ongoing. Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), it has been updated 16 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~May 2022 · 7 months · monthly snapshotRecruiting~May 2022 – ~May 2023 · 12 months · monthly snapshotRecruiting~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Feb 2026 · 13 months · monthly snapshotActive Not Recruiting~Feb 2026 – present · 5 months · monthly snapshot

Change History

16 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Dec 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 11 earlier versions

  1. Sep 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  2. Jul 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  3. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  4. May 2022 — May 2023 [monthly]

    Recruiting PHASE2

  5. Oct 2021 — May 2022 [monthly]

    Recruiting PHASE2

  6. Apr 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  8. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Jul 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  10. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Mar 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
  • Terrence J Bradley, MD
Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations